Literature DB >> 24584043

Living donor liver transplantation with replacement of vena cava for Echinococcus alveolaris: A case report.

Ruslan Mamedov1, Namig Novruzov2, Adil Baskiran3, Fahri Yetisir4, Bulent Unal3, Cemalettın Aydın3, Nuru Bayramov5, Cuneyt Kayaalp3, Sezai Yilmaz3.   

Abstract

INTRODUCTION: There is no medical treatment for alveolar echinococceal disease (AED) of liver till now. Curative surgical resection is optimal treatment but in most advanced cases curative resection can't be done. Liver transplantation is accepted treatment option for advanced AED. AED in some case invade surrounding tissue especially inferior vena cava (IVC). Advanced AED with invasion to IVC can be treated with deceased liver transplantation. Although living donor liver transplantation is very difficult to perform in patients with advanced AED with resected IVC, it come into consideration, since there is very few cadaveric liver. PRESENTATION OF CASE: Here we present a case with advanced stage of AED of liver which cause portal hypertension and cholestasis. AED invaded surrounding tissue, right diaphragm, both lobes of liver and retrohepatic part of IVC. Invasion of IVC forced us to make resection of IVC and reconstruction with cryopreserved venous graft to reestablish blood flow. After that a living donor liver transplantation was done. DISCUSSION: Curative surgery is the first-choice option in all operable patients with AED of liver. Advanced stage of AED like chronic jaundice, liver abscess, sepsis, repeated attacks of cholangitis, portal hypertension, and Budd-Chiari syndrome may be an indication for liver transplantation. In some advanced stage AED during transplantation replacement of retrohepatic part of IVC could be done with artificial vascular graft, cadaveric aortic and caval vein graft.
CONCLUSION: Although living donor liver transplantation with replacement of IVC is a very difficult operation, it should be considered in the management of advanced AED of liver with IVC invasion because of the rarity of deceased liver.
Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Echinococcus alveolaris; Inferior vena cava; Living donor liver transplantation

Year:  2014        PMID: 24584043      PMCID: PMC3955224          DOI: 10.1016/j.ijscr.2014.01.003

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


  13 in total

1.  Orthotopic liver transplantation for incurable alveolar echinococcosis: report of five cases from west China.

Authors:  D Xia; L-N Yan; B Li; Y Zeng; N-S Cheng; T-F Wen; J-Y Yang; Z-H Li; W-T Wang; M-L Yan; X-P Wang; J-G Xie; G-D Pan; J-W Liu
Journal:  Transplant Proc       Date:  2005-06       Impact factor: 1.066

Review 2.  Hepatic echinococcosis: clinical and therapeutic aspects.

Authors:  Giuseppe Nunnari; Marilia R Pinzone; Salvatore Gruttadauria; Benedetto M Celesia; Giordano Madeddu; Giulia Malaguarnera; Piero Pavone; Alessandro Cappellani; Bruno Cacopardo
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

3.  Living donor liver transplantation for alveolar echinococcus is a difficult procedure.

Authors:  S Hatipoglu; B Bulbuloglu; T Piskin; C Kayaalp; S Yilmaz
Journal:  Transplant Proc       Date:  2013-04       Impact factor: 1.066

4.  Experience of liver transplantation for incurable alveolar echinococcosis: a 45-case European collaborative report.

Authors:  Stéphane Koch; Solange Bresson-Hadni; Jean-Philippe Miguet; Jean-Pierre Crumbach; Michel Gillet; George-André Mantion; Bruno Heyd; Dominique-Angèle Vuitton; Anne Minello; Sabine Kurtz
Journal:  Transplantation       Date:  2003-03-27       Impact factor: 4.939

Review 5.  New concepts in organ transplantation.

Authors:  M Haberal; A Dalgic
Journal:  Transplant Proc       Date:  2004-06       Impact factor: 1.066

6.  Liver transplantation in management of alveolar echinococcosis: two case reports.

Authors:  G Moray; R Shahbazov; S Sevmis; H Karakayali; A Torgay; G Arslan; N Savas; U Yilmaz; M Haberal
Journal:  Transplant Proc       Date:  2009-09       Impact factor: 1.066

7.  Long-term experience on surgical treatment of alveolar echinococcosis.

Authors:  Klaus Buttenschoen; Daniela Carli Buttenschoen; Beate Gruener; Peter Kern; Hans G Beger; Doris Henne-Bruns; Stefan Reuter
Journal:  Langenbecks Arch Surg       Date:  2008-07-24       Impact factor: 3.445

8.  Human cystic and alveolar echinococcoses as indication to liver transplantation.

Authors:  L Chomicz; A Szubert; P Fiedor; J Stefaniak; P Myjak; J Zbrowska; J A Polański
Journal:  Transplant Proc       Date:  2003-09       Impact factor: 1.066

9.  Indications and results of liver transplantation for Echinococcus alveolar infection: an overview.

Authors:  Solange Bresson-Hadni; Stéphane Koch; Jean-Philippe Miguet; Michel Gillet; Georges-André Mantion; Bruno Heyd; Dominique-Angèle Vuitton
Journal:  Langenbecks Arch Surg       Date:  2003-08-05       Impact factor: 3.445

10.  Surgical resection of a leiomyosarcoma of the inferior vena cava mimicking hepatic tumor.

Authors:  Junji Ueda; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Masato Yoshioka; Youichi Kawano; Yoshiaki Mizuguchi; Tetsuya Shimizu; Hideyuki Takata; Eiji Uchida
Journal:  Case Rep Med       Date:  2013-02-20
View more
  4 in total

1.  Living related donor liver transplantation with atrio-caval anastomosis of inferior vena cava graft stored in deep-freeze for budd-Chiari syndrome.

Authors:  F Yaylak; V Ince; B Barut; B Unal; M Kilic; S Yilmaz
Journal:  Int J Organ Transplant Med       Date:  2015

2.  Advanced alveolar echinococcosis disease associated with Budd-Chiari syndrome.

Authors:  Vural Soyer; Cengiz Ara; Faik Yaylak; Barış Sarıcı; Mustafa Ozsoy; Okay Koç; Sezai Yılmaz
Journal:  Int J Surg Case Rep       Date:  2015-01-09

3.  Replacement of Vena Cava up to the Right Atrium during Living Donor Liver Transplantation for Echinococcus alveolaris.

Authors:  Fahri Yetişir; S Murad Dogan; Ruslan Mamedov; Cuneyt Kayaalp; Sezayi Yilmaz
Journal:  Case Rep Transplant       Date:  2014-11-20

4.  Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C.

Authors:  Esperance A K Schaefer; James Meixiong; Christina Mark; Amy Deik; Daniel L Motola; Dahlene Fusco; Andrew Yang; Cynthia Brisac; Shadi Salloum; Wenyu Lin; Clary B Clish; Lee F Peng; Raymond T Chung
Journal:  World J Gastroenterol       Date:  2016-12-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.